ArticlePharmaceutical research2026
Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study developed a coordinated-delivery phospholipid-based gel for therapeutics with distinct physicochemical properties to overcome the limitations of current monotherapies for gouty arthritis (GA), achieving synergistic therapeutic effects.
methodsA phospholipid phase-transition gel (RMU-Gel) was prepared via a stirring method to co-encapsulate three agents with distinct physicochemical properties-resveratrol (Res), meloxicam (Melx), and uricase (URE). The study evaluated its in vitro release behavior, in vivo pharmacokinetics, the synergistic effects of Res and Melx, pharmacodynamics in a rat model of gouty arthritis, as well as the preliminary safety and biodegradability of the drug-loaded phospholipid gel.
resultsIn vitro release results showed that RMU-Gel enabled a slow and prolonged release of the drugs in the release medium. The combination of resveratrol and meloxicam significantly enhanced anti-inflammatory and antioxidant responses. In the rat model, a single dose of RMU-Gel provided therapeutic effects lasting over 7 days, outperforming repeated injections of drug suspensions, with excellent safety and biodegradability.
conclusionRMU-Gel offers a simple yet powerful platform for the coordinated co-delivery of physicochemically diverse agents. Specifically, the major breakthrough of this study is the successful co-encapsulation and sustained co-release of three therapeutics with markedly different physicochemical properties within a single phospholipid gel system, thereby preserving their multi-pathway therapeutic synergy. This provides a promising multifunctional strategy for efficient management of gouty arthritis.
Indexed as
Identifiers
42380408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.